Published: April 2020 | Report Code: LS11982 | Available Format: PDF | Pages: 328
The blood screening market revenue stood at $2,402.3 million in 2019, and it is expected to exhibit a CAGR of 8.1% during 2020–2030. The major factors driving the growth of this market are improvements in the blood screening technology, strict regulations regarding contaminated blood, surging healthcare spending, and high prevalence of respiratory, chronic, and infectious diseases.
The reagents and kits category, under the product type segment, held the largest market share in 2019. This was due to the requirement for these products during the first stage of the blood screening procedure and easy availability of several reagents. Besides, the high preference for fast, reliable, and specific detection of transfusion-transmissible diseases (TTD) also fueled the adoption of these products.
The nucleic acid technology (NAT) category, within the technology segment of the blood screening industry, will witness the fastest growth in the foreseeable future. This is because this technology is very popular among blood banks and testing laboratories, on account of its higher sensitivity in comparison to the others.
The human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) category, under the disease type segment, would generate the highest revenue in the blood screening market in 2030. People are mandatorily screened for HIV/AIDS before donating blood to someone. The increasing cases of this disease will, therefore, fuel the growth of this category in the blood screening market. According to the World Health Organization, there were 37.9 cases of HIV/AIDS worldwide in 2018.
In 2019, the blood banks category, within the end user segment of the market for blood screening solutions, accounted for the major share, due to the surging number of blood donation activities and organ transplant surgeries. Moreover, the soaring awareness regarding the dangers of contaminated blood boosted this category’s growth.
North America generated the highest revenue in the market during 2014–2019, due to the high incidence of infectious and respiratory diseases in the region. For instance, North America recorded the highest COVID-19 cases (nearly 560,000) and deaths (around 22,100) till April 13, 2020.
Moreover, the introduction of new products by market players, primarily for COVID testing, such as the CoronaCheck antibody test kit by BioResponse, is also playing a vital role in the growth of the market in the region. Additionally, the rising government support regarding the usage of advanced screening products is also a key growth driver of the blood screening market in this region.
For instance, the Government of Canada encourages the adoption of NAT-based kits and assays for detecting viruses in the blood, even when the antibodies have not been produced in the infected patient and viral genetic material is low.
Rising number of mergers and collaborations among key players has become a prominent trend in the market. For instance, in January 2020, Illumina Inc. and F. Hoffmann-La Roche Ltd. initiated a 15-year, non-exclusive partnership to encourage the usage of distributable next-generation sequencing (NGS)-based oncology testing. Likewise, in April 2019, Ortho-Clinical Diagnostics Inc. launched its D-Dimer assay under its MicroTip partnership assay program. This program was developed by the company in collaboration with Diazyme Laboratories Inc.
Stringent regulations regarding blood contamination have become a key growth driver in the market for blood screening solutions. According to the WHO, in 2015, 123 nations had policies regarding coordinated blood collection, testing, processing, storage, and distribution, whereas 104 countries had specific policies regarding the safety of blood transfusion and quality of the transfused blood. Moreover, the escalating number of blood donations is amplifying the requirement for blood screening, globally.
The WHO states that a total of 117.4 million units of blood are donated every year globally. Of this, 100 million units are collected at 12,700 blood centers in 170 countries.
In recent years, players in the blood screening market have launched a number of new and advanced products, in order to stay ahead of their competitors.
For instance, in September 2019, F. Hoffmann-La Roche Ltd. announced that it received approval from the USFDA for the cobas Babesia test for use on the cobas 6800/8800 systems for individual blood donation testing. It is a commercially available whole blood test to screen donations and follows May 2019 FDA-updated industry guideline recommending screening and testing for Babesia to reduce the risk of transmitting the parasite through transfusions.
Similarly, in February 2019, the FDA approved Grifols S.A.’s Procleix Babesia assay, which can detect ribosomal ribonucleic acid (RNA) of four Babesia species: B. duncani, B. microti, B. venatorum, and B. divergens. The assay can detect these parasites in individual or 16 pooled lysed samples of whole blood or individual blood components.
The major global blood screening market players are Abbott Laboratories, Bio-Rad Laboratories Inc., Becton, Dickinson and Company, General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, Siemens AG, Grifols S.A., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A, J. Mitra & Co. Pvt. Ltd., Bio-Techne Corporation, Trinity Biotech plc, Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE), F. Hoffmann-La Roche Ltd., Danaher Corporation, PerkinElmer Inc., and bioMérieux SA.
|Market Size by Segments||Product Type, Technology, Disease Type, End User|
|Market Size of Geographies||U.S., Canada, Germany, France, Italy, U.K., Spain, Netherlands, Switzerland, Japan, China, India, Australia, South Korea, Singapore, Brazil, Mexico, Saudi Arabia, South Africa|
|Market Players||Abbott Laboratories, Bio-Rad Laboratories Inc., Becton, Dickinson and Company, General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, Siemens AG, Grifols S.A., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., J. Mitra & Co. Pvt. Ltd., Bio-Techne Corporation, Trinity Biotech plc, Blutspendewesen mbH (GFE), Danaher Corporation, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., bioMérieux S.A.|
The blood screening market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
Based on Product Type
Based on Technology
Based on Disease Type
Based on End User
The blood screening market is predicted to demonstrate a CAGR of 8.1% between 2020 and 2030.
The blood screening industry would exhibit rapid expansion in the future years, due to the increasing implementation of strict policies regarding blood contamination in various countries.
Mergers and acquisitions among the major market players is a prominent trend currently being observed in the blood screening market.
The blood banks category, under the end user segment, recorded the highest growth in the blood screening industry in 2019.
Product launch is the key growth strategy of the players in the autoimmune disease diagnostics market.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws